scispace - formally typeset
Open AccessJournal ArticleDOI

Mechanism of angiotensin I converting enzyme inhibition by SQ20,881 (less than Glu-Trp-Pro-Arg-Pro-Gln-Ile-Pro-Pro) in vivo. Further evidence for extrapulmonary conversion.

Suzanne Oparil, +2 more
- 01 Jan 1979 - 
- Vol. 1, Iss: 1, pp 13-22
TLDR
The experiments demonstrated that AI has a pressor effect in the presence of SQ20.881 that is independent of pulmonary conversion, and the data strongly suggest that the systemic vascular bed taken as a whole contains large amounts of AI converting enzyme that is capable of rapid generation of AH without releasing the peptide into circulation.
Abstract
The mechanism by which the angiotensin I (AI) converting enzyme inhibitor SQ20,881 (less than Glu-Trp-Pro-Arg-Pro-Glu-Ile-Pro-Pro) blocks the pressor response to exogenous AI was studied in vivo in the intact anesthetized dog. When administered as a single dose 250 times that of injected AI (250 nmoles/kg) into either the pulmonary or systemic circulation, SQ20,881 produced inhibition of pulmonary conversion of exogenous AI to AII that lasted for more than 6 hours as judged by the absence of immunoreactive or labeled AII in the pulmonary venous effluent. In contrast, the pressor response to exogenous AI began to reappear within 1 hour of SQ20,881 administration. Six hours following SQ20,881, the pressor response to AI had nearly returned to normal, still in the absence of demonstrable intrapulmonary conversion and without release of detectable amounts of AII into the pulmonary venous effluent. These experiments demonstrated that AI has a pressor effect in the presence of SQ20,881 that is independent of pulmonary conversion. Studies with (Des-Asp) AII and (Des-Asp, Arg) AII showed that the delayed pressor response to AI following SQ20,881 administration could not be accounted for by circulating peptide metabolites of AI or AII. A competitive inhibitor of AII, (D-Asp, Ile) AII completely blocked the returning pressor response, suggesting that extrapulmonary generation of AII was responsible. The data strongly suggest that the systemic vascular bed taken as a whole contains large amounts of AI converting enzyme that is capable of rapid generation of AII without releasing the peptide into circulation. The extrapulmonary enzyme is more resistant to long-lasting blockade by SQ20,881 than pulmonary converting enzyme. The physiological role of extrapulmonary conversion systemic and local circulatory homeotasis remains to be assessed.

read more

Citations
More filters
Journal ArticleDOI

An improved fluorometric assay of rat serum and plasma converting enzyme.

TL;DR: The results indicate that, in contrast to human serum, rat serum and plasma contain large and variable amounts of dipeptidase activity that lead to a subestimation of the ACE activity measured in 0.1 M potassium phosphate buffer, pH 8.3, containing 0.3 M NaCl, the most commonly used assay for human serum and tissue ACE.
Journal ArticleDOI

Discrepancy between antihypertensive effect and angiotensin converting enzyme inhibition by captopril.

TL;DR: Blood pressure reduction in the face of normal angiotensin converting enzyme activity is probably due to hyporesponsiveness of the arterioies to pressor hormones, which may be due to specific renin-rdated and/or nonspecific effects of captopril.
Book ChapterDOI

Inhibitors of angiotensin-converting enzyme.

TL;DR: The logical development of this class of therapeutic agents serve as a model for development of specific therapeutic agents in certain other disease states where pathophysiological mechanisms are beginning to be unravelled.
Journal ArticleDOI

Selective activation of the converting enzyme inhibitor MK 421 and comparison of its active diacid form with captopril in different tissues of the rat.

TL;DR: It is demonstrated that in rats MK-diacid is a more potent CE inhibitor than captopril in vitro and in vivo, peripherally and in the brain.
Journal ArticleDOI

Haemodynamic responses to specific renin-angiotensin inhibitors in hypertension and congestive heart failure: a review

TL;DR: The present knowledge of the contribution of the renin-angiotensin system to the vasoconstriction of hypertension and congestive heart failure is summarized, and the haemodynamic consequences of such inhibition are summarised.
References
More filters
Journal ArticleDOI

The preparation of 131i-labelled human growth hormone of high specific radioactivity

TL;DR: The loss of immunological reactivity at high specific radioactivities or at high levels of chemical substitution with STAI/sup 127/!iodine is demonstrated.
Journal ArticleDOI

Solid Phase Peptide Synthesis

TL;DR: This work has shown that effective methods of peptide synthesis are crucial to progress in this area, because only by synthesis can adequate amounts of important peptides be made available for chemical, biologi...
Journal ArticleDOI

Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects

TL;DR: Renin activity increased with Na restriction, was significantly higher on upright activity during both normal and restricted Na intake, and was most markedly elevated following the diuretic.
Journal ArticleDOI

Distribution and properties of angiotensin converting enzyme of rat brain

TL;DR: The broad substrate specificity of the enzymes suggests that, in addition to the possible contribution of the enzyme to the brain renin‐angiotensin system, other naturally occurring peptides might also be substrates for the enzyme.
Journal ArticleDOI

Inhibition of homogeneous angiotensin-converting enzyme of rabbit lung by synthetic venom peptides of Bothrops jararaca.

TL;DR: The nonapeptide, SQ 20 881, appears to be the best of the synthetic venom peptides for use in studying the role of the renin (EC 3.4.15)-angiotensin system in physiological and pathological processes.
Related Papers (5)